Skip to main content
SpringerLink
Log in

Adalimumab

In Psoriatic Arthritis

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Adalimumab, a fully human monoclonal antibody, is a tumour necrosis factor antagonist that has been investigated for efficacy in psoriatic arthritis, based on well-established use of the drug in rheumatoid arthritis.

  • ▴ In well-controlled Phase III trials, adalimumab (40 mg administered subcutaneously every other week) has shown efficacy in adult patients with psoriatic arthritis who had an inadequate response to previous treatment with NSAIDs (24-week ADEPT trial; n = 313) or disease-modifying antirheumatic drugs (12-week study; n = 100).

  • ▴ In these trials, adalimumab recipients experienced a significantly greater improvement in arthritis response (p < 0.001 in the ADEPT trial, and p ≤ 0.05 in the smaller study) than placebo recipients, as assessed by the ACR20, ACR50 and ACR70 response rates.

  • ▴ There was radiographic evidence of progressive joint damage in the placebo group but not the adalimumab group at 24 weeks in the ADEPT trial, according to the mean total Sharp score modified for psoriatic arthritis.

  • ▴ The signs and symptoms of psoriasis in patients with psoriatic arthritis were clinically and statistically more improved with adalimumab than with placebo, according to the PASI responses, at 12 and 24 weeks in the ADEPT trial (e.g. PASI50 rate 75% vs 12% at 24 weeks; p < 0.001).

  • ▴ Adalimumab was generally well-tolerated in clinical trials of psoriatic arthritis; the adverse event profile appears to be similar to that associated with use of the drug in rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for identification purposes only and does not imply endorsement.

References

  1. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. Drugs 2005; 65(9): 1223–38

    Article  PubMed  CAS  Google Scholar 

  2. Kyle S, Chandler D, Griffiths CE, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005 Mar; 44(3): 390–7

    Article  CAS  Google Scholar 

  3. Griffiths CE, Iaccarino L, Naldi L, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006 Jan; 24 Suppl. 40: S72–8

    PubMed  CAS  Google Scholar 

  4. Finucane KA, Archer CB. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus. Clin Exp Dermatol 2005; 30(2): 201–4

    Article  PubMed  CAS  Google Scholar 

  5. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52(1): 1–19

    Article  PubMed  Google Scholar 

  6. Prasad R, Gladman D. Current and investigational treatment of psoriatic arthritis. Expert Opin Invest Drugs 2004; 13(2): 139–50

    Article  CAS  Google Scholar 

  7. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004 Jul; 63(7): 755–8

    Article  PubMed  CAS  Google Scholar 

  8. Ruderman EM, Tambar S. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin 2004; 22(4): 477–86

    Article  PubMed  Google Scholar 

  9. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Biodrugs 2005; 19(1): 47–57

    Article  PubMed  CAS  Google Scholar 

  10. Bang LM, Keating GM. Adalimumab; a review of its use in rheumatoid arthritis. Biodrugs 2004; 18(2): 121–39

    Article  PubMed  CAS  Google Scholar 

  11. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 2005 Nov; 5(11): 1491–504

    Article  PubMed  CAS  Google Scholar 

  12. Kavanaugh A, Greenwald M, Zizac T, et al. Immune response is not affected by adalimumab therapy [abstract no. THU0196]. Ann Rheum Dis 2003; 62 Suppl. 1: 169

    Google Scholar 

  13. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci 2005; 1051 (559-569)

    Google Scholar 

  14. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 May; 63(5): 508–16

    Article  PubMed  Google Scholar 

  15. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003 Jan; 48(1): 35–45

    Article  PubMed  CAS  Google Scholar 

  16. Abbott Laboratories. Humira® (adalimumab): prescribing information, 2005 Oct

  17. Velagapudi RB, Noertersheuser PA, Awni WM, et al. Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA™, Abbott) following a single intravenous injection [abstract no. 258]. Arthritis Rheum 2003; 48 (9 Suppl.): S141

    Google Scholar 

  18. Awni WA, Cascella P, Napoleaon A, et al. Steady-state pharmacokinetics (PK) of adalimumab (HUMIRA tm, Abbott) following 40mg subcutaneous (sc) injection every other week (eow) in rheumatoid arthritis (RA) patients with or without methotrexate (MTX) background therapy [abstract no. 255]. Arthritis Rheum 2003; 48 Suppl. 9: S140

    Google Scholar 

  19. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol 2005; 32 Suppl. 74: 13–8

    Google Scholar 

  20. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Sem Arthritis Rheum 2005; 34 (5 Suppl.): 12–8

    Article  CAS  Google Scholar 

  21. van de Putte LBA, Salfield J, Kaymakcalan Z. TNF (a)-inhibition in the treatment of rheumatoid arthritis. In: Moreland LW, Emery P, editors. Adalimumab. London: Martin Dunitz, 2003: 71–93

    Google Scholar 

  22. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 Oct; 52(10): 3279–89

    Article  PubMed  CAS  Google Scholar 

  23. Genovese MC, Mease PJ, Thomson GTD, et al. Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy [abstract no. FRI0187]. Ann Rheum Dis 2005; 64 Suppl. III: 313. EULAR Annual European Congress of Rheumatism; 2005 8–11 Jun; Vienna

    Google Scholar 

  24. Mease PJ, Sharp JT, Ory P, et al. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT [abstract no. FRI0212]. Annual European Congress of Rheumatology, Jun 8–11 2005, Vienna. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 320

    Google Scholar 

  25. Gladman DD, Mease PJ, Emery P, et al. Adalimumab treatment effects on quality of life in patients with psoriatic arthritis: results from ADEPT [abstract no. FRI0203]. Ann Rheum Dis 2005; 64 Suppl. III: 317. EULAR Annual European Congress of Rheumatology; 2005 Jun 8–11; Vienna

    Google Scholar 

  26. Guh D, Bansback NJ, Nosyk B, et al. Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira (Rm)) [abstract no. FRI0476]. Ann Rheum Dis 2005: 64 Suppl. III: 401. ISPOR 8th Annual European Congress; 2005 6–8 Nov; Florence

    Google Scholar 

  27. Kavanaugh AF, Ritchlin CT, Malaise MG, et al. Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: results from ADEPT [abstract no. FRI0227]. Ann Rheum Dis 2005; 64 Suppl. III: 325. EULAR Annual European Congress of Rheumatology; 2005 Jun 8–11; Vienna

    Google Scholar 

  28. Mease PJ, Gladman DD, Ritchlin CT, et al. Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT [abstract no. 500]. Arthritis Rheum 2005; 52 (Suppl. 9): 215. Annual Scientific Meeting of the American College of Rheumatology; 2005 Nov 12–17; San Diego

    Google Scholar 

  29. Mease P, Gladman D, Ritchlin C, et al. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial [abstract no. P2864]. J Am Acad Dermatol 2006; 54 Suppl. 1: AB214

    Google Scholar 

  30. Gladman D, Mease P, Kavanaugh A, et al. Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis of moderate versus severe psoriasis in the ADEPT trial [abstract no. P40]. J Am Acad Dermatol 2006: 54 Suppl. 1: AB10–11

    Google Scholar 

  31. Anis AH, Guy D, Melilli LE. Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira Rm) [abstract no. PAR12]. Value Health 2005; 8: A27. Plus poster presented at the 8th International Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6–8; Florence

    Article  Google Scholar 

  32. Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): ii49–54

    Article  PubMed  Google Scholar 

  33. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies [published erratum appears in JAMA 2006; 295 (21): 2482]. JAMA 2006; 295(19): 2275–85

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Dene Simpson & Lesley J. Scott

Authors
  1. Dene Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dene Simpson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, D., Scott, L.J. Adalimumab. Drugs 66, 1487–1496 (2006). https://doi.org/10.2165/00003495-200666110-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666110-00008

Keywords

Search

Navigation